T-cell Infusion Targeting BCMA and CD19 for Refractory/Relapsed Systemic Lupus Erythematosus (SLE) Patients With or Without Organs Involvement.

A clinical trial, NCT06350110, is being conducted in China by Essen Biotech to investigate the use of BH002 injection (CD19-BCMA CAR-T cells) in treating patients with resistant systemic lupus erythematosus (SLE). The trial aims to determine the highest dose of the injection that patients can tolerate. SLE is an autoimmune disorder characterized by the production of autoantibodies, and conventional treatment aims to achieve remission. CD19-BCMA CAR-T cells offer a potential solution by targeting and eliminating abnormal B cells responsible for antibody production. The trial will evaluate the safety and effectiveness of this new treatment approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy for patients with specific hematologic malignancies. The treatment regimen involves the administration of fludarabine phosphate and cyclophosphamide before the infusion of CD19/BCMA-CAR T cells. Eligible patients may receive additional doses if they respond well to the initial infusion. The trial is not yet recruiting and is estimated to be completed by December 2025. [Extracted from the article]